The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application to treat metastatic colorectal carcinoma in patients who failed previous ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...

In January, the U.S. Food and Drug Administration (FDA) cleared Mineralys Therapeutics’ Investigational New Drug (IND) Application for a Phase 2 trial of lorundrostat for moderate-to-severe ...

Researchers have developed a drug shown to significantly extend survival time for patients with glioblastoma, the most common primary brain tumor in adults, according to results of a new trial.

Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...